Notify me when Teoxane SA files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| RVNC | Revance Therapeutics, Inc. | Common Stock, par value $0.001 per share | 6.2% | $32,335,404 | 6,550,800 | 0% | Teoxane SA | 30 Jan 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|